Morgan Stanley downgraded Zentalis to Equal Weight from Overweight.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zentalis Pharmaceuticals Engages with Investors at Conferences
- Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- Zentalis Pharmaceuticals Appoints Luke Walker to Board